Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 11/20 | 0.42 |
| ▸ | GIPR | P48546 | 11/20 | 0.42 |
| ▸ | GLP1R | P43220 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643423 | 1.00 | GCGR (0.42) | GCGRGIPRGLP1RCNR1CNR2 | |
| SCHEMBL2643418 | 1.00 | GCGR (0.42) | GCGRGIPRGLP1RCNR1CNR2 | |
| SCHEMBL2643708 | 1.00 | GCGR (0.42) | GCGRGIPRGLP1RCNR1CNR2 | |
| SCHEMBL2644721 | 1.00 | GCGR (0.42) | GCGRGIPRGLP1RCNR1CNR2 | |
| SCHEMBL2643975 | 0.92 | GCGR (0.39) | GCGRGIPRGLP1RCNR1LTB4R2 | |
| SCHEMBL2644086 | 0.92 | GCGR (0.39) | GCGRGIPRGLP1RCNR1LTB4R2 | |
| SCHEMBL2643499 | 0.92 | GCGR (0.39) | GCGRGIPRGLP1RCNR1LTB4R2 | |
| SCHEMBL2644303 | 0.92 | GCGR (0.39) | GCGRGIPRGLP1RCNR1LTB4R2 | |
| SCHEMBL2643503 | 0.92 | GCGR (0.39) | GCGRGIPRGLP1RCNR1LTB4R2 | |
| SCHEMBL2643161 | 0.85 | GCGR (0.58) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509509-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-03-02 | — | — | EP | claimed |
| WO-2003097619-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2003-11-27 | — | — | WO | claimed |
| EP-1509509-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097619-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.